Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.
View/ Open
Date
2017-03-01Author
Smyth, EC
Babina, IS
Turner, NC
Type
Journal Article
Metadata
Show full item recordAbstract
<b/>FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations in FGFR2 and intratumoral heterogeneity drive resistance in patients with FGFR2-translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic. Cancer Discov; 7(3); 248-9. ©2017 AACR.See related article by Goyal et al., p. 252.
Collections
Subject
Bile Ducts, Intrahepatic
Humans
Cholangiocarcinoma
Bile Duct Neoplasms
Liver Neoplasms
Mutation
Receptor, Fibroblast Growth Factor, Type 2
Research team
Molecular Oncology
Language
eng
Date accepted
2017-02-01
License start date
2017-03
Citation
Cancer discovery, 2017, 7 (3), pp. 248 - 249
Publisher
AMER ASSOC CANCER RESEARCH